105cats
IID · 2019
Active Fel d 1 on the coat
Significant reduction from week 3; an average reduction of about 47% later in the study
View DOI ↗SCIENCE & EVIDENCE
OKCLEAR Evidence
Understand the pathway, examine the evidence boundaries
OKCLEAR separates published science, product-specific testing and commercial statements so each type of conclusion can be assessed against its own evidence.
PUBLIC RESEARCH
Published research background
The published studies below explain the scientific background for cat allergens and the IgY route. Unless stated otherwise, they are not OKCLEAR finished-product test results.
26weeks
Frontiers · 2020
Adult cat safety
No ingredient-related adverse effects observed under the test conditions
View DOI ↗84days
Frontiers · 2024
Kitten safety
27 kittens in a randomized blinded controlled study; no biologically meaningful adverse changes
View DOI ↗42people
MASK-air · 2024
Human home observation
After one month, overall, nasal, ocular and symptom–medication scores all showed improvement
View DOI ↗Different products and published studies may use different samples, assays, time points and endpoints, so no head-to-head superiority comparison is made. Conclusions depend on the applicable SKU and evidence materials.
SCIENCE & EVIDENCE
Evidence pathway
OKCLEAR separates published science, product-specific testing and commercial statements so each type of conclusion can be assessed against its own evidence.
MECHANISM
Specific IgY binds Fel d 1
Published research validates the molecular mechanism of source-side management with egg-yolk antibodies.
CAT STUDIES
Active Fel d 1 falls in saliva and on the coat
In a 105-cat study, significant change appeared from week 3, with an average reduction of about 47% later in the study.
HUMAN HOME STUDY
Multiple symptom scores improved after one month
The 2024 MASK-air study recorded changes in overall, nasal, ocular, asthma and symptom–medication scores.
EPITOPE ENGINEERING
2026 study: 23 cats, 4 weeks
Salivary Fel d 1 fell by about 50%–71% in some dose groups, showing the R&D potential of multi-epitope antigens and specific IgY.
SAFETY
Use and safety boundaries
- OKCLEAR products do not diagnose, prevent or treat human allergic disease, and they do not make a cat allergen-free.
- Published results come from specific formulations, doses and test conditions; they are not automatically results for an OKCLEAR finished product.
- Product indicator conclusions depend on the applicable SKU, batch, sample, assay, time point and test condition.
- Seek urgent medical care for breathing difficulty, blue lips or face, severe wheezing, or rapidly worsening throat symptoms.
RESEARCH BACKGROUND
Started by a team with a Zhejiang University pet-nutrition research background
This statement describes the team’s research background. It does not mean OKCLEAR is an official Zhejiang University product, produced by the university, or officially endorsed by it.
PUBLIC RESEARCH
Request technical materials
The link opens your own email client. Where applicable we sign an NDA first, then share approved specification, quality and compliance materials.